Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

(2016) I. Azzaoui et al.   BLOOD

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

(2015) Dohee Kwon et al.   HISTOPATHOLOGY

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial

(2014) S. Riihijarvi et al.   HAEMATOLOGICA

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer

(2012) M J Proctor et al.   BRITISH JOURNAL OF CANCER

Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group

(2011) Naoki Wada et al.   HISTOPATHOLOGY

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

(2011) R A Wilcox et al.   LEUKEMIA

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma

(2010) Matthew T. Drake et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY